News & Updates

Expert shares lessons from COVID-19

06 Dec 2023 by

The world is out of the pandemic, but several subvariants of Omicron are still evolving, says Dr Adrian Chan, respiratory physician and intensivist at Mount Elizabeth Novena Hospital, Singapore, during his talk at APSR 2023.

Expert shares lessons from COVID-19

06 Dec 2023

Prepregnancy energy drink consumption may raise gestational hypertension risk

05 Dec 2023

Women who consume energy drinks before pregnancy may potentially be at increased risk of gestational hypertension, as reported in a study.

Prepregnancy energy drink consumption may raise gestational hypertension risk

05 Dec 2023

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

05 Dec 2023 by

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

05 Dec 2023

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

05 Dec 2023

Combination therapy does not appear to have beneficial effects in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and incidence of adverse events compared with monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) who failed first-line treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, a study has shown.

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

05 Dec 2023

NOACs help improve outcomes in AF with vascular disease

05 Dec 2023 by

A history of vascular disease appears to contribute to worse long-term outcomes in patients with atrial fibrillation (AF), but treatment with oral anticoagulation (OAC) helps, suggests a recent study.

NOACs help improve outcomes in AF with vascular disease

05 Dec 2023

Novel therapies tied to drop in colectomy rate in paediatric UC

05 Dec 2023

The risk of colectomy in paediatric onset ulcerative colitis (UC) has significantly decreased at the population level along with an increase in the use of immunosuppressants and antitumour necrosis factor (anti-TNF), reports a study.

Novel therapies tied to drop in colectomy rate in paediatric UC

05 Dec 2023

Remibrutinib improves CSU symptoms in phase III trials

05 Dec 2023 by

Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.

Remibrutinib improves CSU symptoms in phase III trials

05 Dec 2023

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

05 Dec 2023 by

In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

05 Dec 2023

HPV self-sampling with isothermal amplification detection may become part of cervical cancer screening

05 Dec 2023 by

A prospective study in women attending a colposcopy clinic in Hong Kong supports the use of self-sampling with an isothermal amplification (AmpFire)–based assay for human papillomavirus (HPV) detection in cervical cancer screening, showing substantial agreement with clinician sampling using either the AmpFire-based or polymerase chain reaction (PCR)–based reference assay.

HPV self-sampling with isothermal amplification detection may become part of cervical cancer screening

05 Dec 2023

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

05 Dec 2023

Treatment with fezolinetant 45 mg outperforms other nonhormone therapies (non-HTs) in terms of minimizing the frequency of moderate-to-severe vasomotor symptoms (VMS) in women undergoing menopause, according to a study from the US.

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

05 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Expert shares lessons from COVID-19

Expert shares lessons from COVID-19

Prepregnancy energy drink consumption may raise gestational hypertension risk

Prepregnancy energy drink consumption may raise gestational hypertension risk

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?

NOACs help improve outcomes in AF with vascular disease

NOACs help improve outcomes in AF with vascular disease

Novel therapies tied to drop in colectomy rate in paediatric UC

Novel therapies tied to drop in colectomy rate in paediatric UC

Remibrutinib improves CSU symptoms in phase III trials

Remibrutinib improves CSU symptoms in phase III trials

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

HPV self-sampling with isothermal amplification detection may become part of cervical cancer screening

HPV self-sampling with isothermal amplification detection may become part of cervical cancer screening

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause